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Abstract
Caudate dysfunction is implicated in schizophrenia. However, little is known about the relationship
between aggression and caudate volumes. Forty-nine patients received magnetic resonance imaging
scanning in a double-blind treatment study in which aggression was measured. Caudate volumes
were computed using a semiautomated method. The authors measured aggression with the Overt
Aggression Scale and the Positive and Negative Syndrome Scale. Larger caudate volumes were
associated with greater levels of aggression. The relationship between aggression and caudate
volumes may be related to the iatrogenic effects of long-term treatment with typical anti-psychotic
agents or to a direct effect of schizophrenic processes on the caudate.
A large and rapidly growing literature in magnetic resonance imaging has shown that several
regional brain volumes differ between schizophrenia patients and healthy comparison subjects.
1 Many of these studies have found that regional parenchymal volumes, such as medial
temporal and inferior parietal regions, are larger in healthy subjects than in schizophrenia
patients. However, the reverse is also found, especially in the basal ganglia.
The meaning of larger regional brain volumes in schizophrenia is unclear. Larger volumes in
patients may reflect larger numbers of neurons, increased neuronal size, reduced neuronal
density with an equivalent number of neurons, edema, or other pathological processes.
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Studies of the neurobiology of aggression suggest that, in general, higher levels of aggression
are associated with abnormal brain structure2 and function.3
The relationship between caudate nuclei and aggression has apparently not been studied
systematically, but several lines of evidence imply that abnormal function in basal ganglia
regions may be associated with aggression and psychopathy.4–10
However, no prior study addresses the specific relationship between caudate volumes and
aggression in treatment-resistant schizophrenia patients. Given the findings described above,
variations in caudate volumes might have implications for the pathophysiology of aggression.
We chose to examine these relationships in exploratory analyses.
METHOD
Participants
Treatment-resistant patients with schizophrenia or schizoaffective disorder (N = 157)
participated in a 14-week study comparing clozapine, olanzapine, risperidone, and haloperidol
in treatment-resistant schizophrenia11 at four participating sites. A subset of 62 patients
received a magnetic resonance imaging (MRI) scan at baseline. Thirteen scans were unusable
due to poor scan quality or other technical problems. Thus, the final sample consisted of 49
patients (six women). These participants were an unselected subset of study participants who
consented to and could tolerate MRIs. The MRI portion of the study started after the beginning
of the larger project, and patients were enrolled in this sub-study using a separate consent form.
All eligible patients at sites with access to the MRI (Dorothea Dix Hospital at the University
of North Carolina [UNC], Nathan Kline Institute on the grounds of Rockland Psychiatric Center
[NKI], Manhattan Psychiatric Center [MPC]) were invited to participate in this substudy. None
was excluded due to aggressivity.
Diagnoses were obtained using the Structured Clinical Interview for DSM-IV Axis I
Disorders–Clinician Version (SCID-CV).12 Of the 49 patients in the study, 25 (51%) had a
comorbid alcohol use diagnosis (dependence or abuse), and 29 (59%) had a comorbid substance
use diagnosis. All patients were hospitalized and were presumed to be free of current alcohol
and substance abuse.
Included subjects had a mean age of 41.5 (SD = 8.2) years. Mean age of onset, conservatively
defined as age at first psychiatric hospitalization, was 22.8 (SD = 5.11) years, and patients had
a mean duration of illness of 18.6 (SD = 7.7) years. Of the 49 patients, 10 were assigned to
treatment with clozapine, eight with haloperidol, 18 with olanzapine, and 13 with risperidone.
All subjects gave written informed consent to participate in the study.
MRI
Acquisition—Patients were scanned with the 1.5T Siemens Vision system (Erlangen,
Germany) at NKI’s Center for Advanced Brain Imaging and with the 1.5T GE Signa system
(Milwaukee) located at UNC. For each subject a magnetization prepared rapidly acquired
gradient echo (MPRAGE; on Siemens scanners) or spoiled gradient recall (SPGR; on GE
scanners) scan was collected in the axial plane parallel to the plane connecting the anterior and
posterior commissures (AC-PC plane). These scans were used for anatomical measurements.
For scans collected at NKI, the scan parameters were repetition time (TR) = 13.5 msec, echo
time (TE) = 7 msec, Field of View (FOV) = 240 mm, matrix = 256×256, 124 slices, slice
thickness = 1.5 mm, no gap. For scans collected at UNC, the scan parameters were TR = 15
msec, TE = 2.2 msec, FOV = 240 mm, matrix = 256×256, 124 slices; slice thickness = 1.5 mm,
no gap, 1 NEX.
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A dual echo scan was also acquired for use in segmentation; this scan provided T2- and proton
density (PD)-weighted scans. The UNC sequence had TR = 4000ms, TE = 20/100ms, FOV =
20 mm, matrix = 256×256, slice thickness = 3 mm, no gap. The NKI sequence had TR =
6250ms, TE = 16/98ms, FOV = 240 mm, matrix = 256×256, slice thickness = 3 mm, no gap.
Although imaging parameters varied by site, volumes are reported in cubic centimeters, which
allows direct comparisons of data across sites. No site differences were found when they were
explicitly examined in an analysis of variance (ANOVA), in which each volumetric
measurement of interest was a dependent variable and study site (UNC, NKI) was a between-
subjects factor.
Image Processing—Images were registered to the Talairach space using the mutual
information method MIRIT.13 We used EMS software (Expectation Maximization
Segmentation) developed by Van Leemput et al.14 to create a segmentation file of brain gray
matter, white matter, and cerebrospinal fluid (CSF). For the segmentation, the T1 was
downward-interpolated to the FSE dimensions. The three scans, T1 (down sampled), PD, and
T2 weighted were used as three separate input channels, and segmented using the EMS
processing package. A single composite color map file of brain tissue and CSF was produced
as output. The T2 gray level image was then used in conjunction with the segmentation file to
complete segmentation of subcortical structures.
The caudate nucleus segmentation was performed using IRIS software (available at http://
midag.cs.unc.edu) by a single rater who was blind to patient identity, medical history, and
patient aggression data. The colored segmentation file was loaded over the grayscale in IRIS.
Caudate masking was accomplished by selecting the gray matter label for overpainting in the
IRIS window. The gray matter of the caudate on the segmentation file was then masked with
a new color label. The head of the caudate nucleus was segmented in the axial view.
Segmentation started at the most superior aspect of the lateral ventricle where gray matter of
the caudate was found. The ventricle was the medial boundary. The lateral boundary was
determined by the edge of the gray matter of the caudate head and white matter of the internal
capsule. The volumes of new color labels for right and left caudate were obtained through IRIS.
All segmentation procedures at the UNC Neuroimaging lab are validated with a standardized
intra- and interrater reliability. For interrater reliability, five cases replicated three times and
blind to raters are segmented by at least two raters to validate the protocol. These protocols are
used in many different studies which include segmentation by multiple raters and of left and
right structures. The interrater reliability for left and right caudate was above 0.95. The
intrarater reliability was performed on five cases measured twice and exceeded 0.99 for both
left and right caudate. The display, along with rendered caudate volumes, is shown in Figure
1. Separate gray matter, white matter, and cerebrospinal fluid hemispheric volumes were
generated automatically using AVS software.
Exposure to Typical Antipsychotic Drugs
We did not have access to the lifetime history of anti-psychotic drug treatment. As a proxy,
we used duration of illness, defined as the period since the age at first hospitalization, to
estimate the number of years patients had been treated with typical antipsychotic drugs. We
think that this measure provides a reasonable estimate of exposure to typical antipsychotic
drugs. Among the atypical antipsychotic drugs, only clozapine and risperidone were
commercially available prior to the start of this study, whereas olanzapine received FDA
approval only during the course of this study. Thus, it is unlikely that patients in this study
received substantial exposure to atypical antipsychotic drugs.
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Antipsychotic Efficacy and Safety
We rated psychiatric symptomatology at baseline and throughout the study using the Positive
and Negative Syndrome Scale (PANSS).15 Raters were trained to an interrater reliability of
ICC ≥0.93 with the criterion rater (J-PL). (For more details on PANSS administration and
ratings, see Volavka et al.11)
To assess extrapyramidal symptoms, we administered the Extrapyramidal Symptom Rating
Scale (ESRS).16 The mean total score and akathisia rating was used in covariate analyses.
Aggression Data
Individual incidents of aggression were recorded using the Overt Aggression Scale (OAS).
17 Twenty-one patients (43%) exhibited at least one aggressive incident (verbal or physical)
during the 14-week study period, whereas the remaining patients had no incidents.
Accordingly, we created a binary variable labeled “incident status” (no incidents = 0, one or
more incidents = 1). In addition, we obtained the log-transformed Total Aggression Severity
(TAS) score, which is derived from the OAS, during the 14-week double-blind study.
The method by which TAS was computed is described elsewhere.18 Briefly, for each
aggressive incident, a severity score was computed by summing weighted scores of all OAS
subscales that applied (e.g., verbal aggression and physical aggression against others frequently
coincided in the same incident, and thus the scores on these subscales were summed). The
weights were assigned using an algorithm developed by the OAS authors (e.g., verbal
aggression has a lower weight than physical assault). The weighted scores for individual
subscales range from 1 (lowest severity of verbal aggression like angry shouting) to 6 (physical
aggression against self or other people, resulting in serious injuries). The Total Aggression
Severity score (TAS) was obtained by summing these weighted scores for individual incidents
over time (if there were multiple incidents) for each individual patient. Thus, the TAS reflects
the seriousness and the number of incidents during the period of randomized treatment.
The PANSS Hostility item was also used as a measure of aggression. We have used this measure
in other studies to examine relationships between medication effects and aggression.19,20 We
also used the Poor Impulse Control item of the PANSS as a secondary measure, because it is
specifically related to disordered regulation and control of action on inner urges. Thus, four
variables were used to describe aggressive behavior: incident status, TAS, PANSS Hostility,
and PANSS Poor Impulse Control. Because of a skewed and restricted range, the latter two
variables were dichotomized, with scores of 1 (minimum score) being coded as 1 and scores
of greater than 1 being coded as 2.
Statistical Analysis
The p = 0.05 level (two-sided, comparisonwise) was adopted for all statistical analyses. No
correction for test multiplicity was used because of the exploratory nature of the analyses.
Aggression measures served as dependent variables in separate general linear model (GLM)
analysis (for continuous measures [TAS and PANSS Hostility score]) or logistic regression
analysis (for dichotomous measures [incident status and PANSS Impulse Control]). Caudate
volumes were used as independent variables. Intracranial volume and age were applied as
covariates. In addition to these principal analyses, associations of regional caudate
morphometric measures with potentially important demographic variables (age, duration of
illness, total head size) and clinical symptoms reflecting acute and chronic exposure to
antipsychotic drug treatment (total ESRS scores and akathisia) were investigated with bivariate
correlation analysis.
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As noted above, 43% of patients had at least one aggressive incident during the 14-week study
period. The subjects had a mean TAS score of 6.83 (SD = 17.6), a mean PANSS Impulse
Control score of 1.67 (SD = 1.04), and a mean PANSS Hostility score of 2.05 (SD = 1.28).
Patients had a mean brain volume of 1,204.04 (SD = 113.88) cc, with a mean white matter
volume of 429.25 (SD = 39.7) cc, a mean gray matter volume of 608.2 (SD = 62.6) cc, and a
mean CSF volume of 167.5 (SD = 27.8) cc. Patients had a left caudate volume of 4.0 (SD =
0.6) cc, a right caudate volume of 4.2 (SD = 0.6) cc, and a total caudate volume of 8.2 (SD =
1.1) cc.
Relationships between caudate volumes and aggression are shown in Table 1. Larger left
caudate volumes were associated with higher TAS scores during the study period. Moreover,
regarding the incident status, patients who had any aggressive incident had larger caudate
volumes than did those who had no such incidents. This pattern seemed particularly prevalent
on the left. Finally, left caudate volumes were larger in patients with lesser degrees of impulse
control, with a similar trend for total caudate volumes.
Left caudate volumes were inversely correlated with age (r = −0.30, p = 0.04). However,
caudate volumes did not correlate significantly with the duration of illness. Finally, controlling
for age and intracranial volume, ESRS scores did not correlate with caudate volumes.
We conducted additional analyses with gender, substance use disorder, and alcohol use disorder
as covariates. The results using these covariates were essentially unchanged from those
discussed above.
DISCUSSION
The primary finding of this study was that larger caudate volumes were associated with
aggressive behavior. These results were independent of effects due to age, alcohol use
disorders, or substance use disorders.
Previous work suggested that treatment with typical antipsychotic drugs increases caudate
volumes. Basal ganglia volumes are increased in patients with schizophrenia in vivo (using
MRI)21,22 and post-mortem.23 This increase may vary with treatment history. Schizophrenia
patients who had been treated with typical antipsychotic drugs showed increases in the volume
of the caudate.24,25 In a post-mortem study in rats, chronic treatment with haloperidol was
associated with increased striatal volumes.26 Thus, the effect of haloperidol on striatal volumes
in patients may be related to treatment rather than to the pathophysiology of schizophrenia. In
further support of this argument, when patients were switched to clozapine, an atypical
antipsychotic drug, caudate volumes were reduced.27,28 Interestingly, clozapine has well-
known antiaggressive effects in schizophrenia.3,29
The duration of typical antipsychotic drug treatment may be related to increases in volume of
the basal ganglia,30 suggesting that the effects of such treatment may be cumulative. However,
in the current study, duration of illness did not account for the relationships between caudate
and ventricular volumes and outcome. It is possible that long-term treatment with typical
antipsychotic drugs had a nonlinear relationship with the volume increase we measured. The
effects may plateau after a certain period of exposure to typical neuroleptics, with no further
progression.
The mean duration of patients’ treatment with typical antipsychotic drugs (estimated by the
time elapsed since first hospitalization) was 18.6 years. Treatment resistance to antipsychotic
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drugs was an eligibility criterion for participation in this study. In the past, treatment resistant
patients, particularly those showing persistent aggressive behavior, were treated with ever
increasing doses of typical antipsychotic drugs. Clinically unsuccessful as it was, such high-
dose treatment may have resulted in cumulative effects on the caudate. Thus, the relation
between caudate size and aggression we observed could have arisen as an epiphenomenon:
patients failed to respond, were aggressive, therefore received high-dose long-term treatment
with antipsychotic drugs, and that treatment coincidentally resulted in caudate volume increase.
If this was true, the caudate volume increase was a consequence (rather than an antecedent) of
aggression, and it was mediated by treatment with antipsychotic drugs.
However, this iatrogenic mechanism may not fully explain the observed relation between
caudate size and aggression. Long-term treatment of nonresponding aggressive patients is not
necessary for a caudate volume increase: the caudate volume was reported to increase early in
the first year of treatment even in first-episode patients responding to pharmacotherapy.24
Consistent with that observation,24 an increase in striatal blood flow was reported in first-
episode, neuroleptic-naïve schizophrenia patients after the initiation of pharmacotherapy.31
Our lack of finding a significant relationship between caudate volume increase and duration
of illness also points to other contributing factors. Striatal blood flow may be related to
antipsychotic31 treatment as well as to aggression.9
Caudate dysfunction, perhaps independently of its origin (pharmacological or otherwise), may
interfere with the normal functioning of the frontal-subcortical circuitry. Cummings5 proposed
a prefrontal-subcortical circuit, including the caudate, corresponding to the orbitofrontal lobe
neurobehavioral syndromes. Empirical observations indicate that penetrating brain wounds
causing frontal medial lesions were associated with more aggressive behavior than lesions to
other brain areas.32 Consistent with these ideas, Hoptman et al.33,34 found significant negative
correlations between white matter integrity, as measured using diffusion tensor imaging, and
both impulsivity and aggression in a variety of areas, including the caudate. Because white
matter tracts play an important role in the connectivity of the brain, the disruptions of white
matter integrity in the regions mentioned may well have implications for the orbitofrontal
syndrome.
The current findings have implications for the interpretation of studies in which the relationship
between functional outcome and brain volumes is studied. Thus, for volumetric studies of
schizophrenia, it is important to know the patients’ treatment history.
The study has some important limitations. The subjects who received the MRI may not be
representative of treatment-resistant schizophrenia patients, or even of the small sample from
which they were selected. In addition, the sample was not specifically sampled for a high rate
of aggressive incidents. Finally, we did not have information on head injury or criminal history
in these patients.
In conclusion, in this sample of patients with treatment-resistant schizophrenia, larger caudate
volumes were associated with aggression. This association may be due to treatment with
antipsychotic drug, to the pathophysiology of schizophrenia, or to a combination of these two
mechanisms.
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(Left) Axial (upper left), Sagittal (upper right), and Coronal (bottom right) Views of the
Segmented Brain. (Right) Enlargement of Rendered Caudate Volumes
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